TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02450864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ESWT
Description: Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD \>270degrees.
Study: NCT03173443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single lumen tube and bronchial blocker
Description: fiberoptic intubation with single lumen tube and bronchial blocker

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double lumen tube
Description: fiberoptic intubation with double umen tube
Study: NCT02878070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calls from a Peer Health Coach for 6 months
Description: Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
Study: NCT03442166

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LED group
Description: The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham group
Description: Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
Study: NCT04520334

Intervention type: OTHER
Group type: OTHER
Intervention: Zhineng Qigong intervention
Description: The intervention consisted of group activities which were performed in one group, as lectures, demonstrations, and Zhineng Qigong training, all planned and led by European Zhineng Qigong.~The group activities were performed during four weekends (12 hours each) and weekly training two times per week (each for two hours). Introductory lecture (two hours) was given at the evening before the first weekend. The respondents were recommended daily Zhineng Qigong training with help of an instructional training CD.
Study: NCT01731769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum assisted closure in experimental arm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary dissection
Study: NCT01772680

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplementation
Description: 25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
Study: NCT03721588

Intervention type: OTHER
Intervention: Clinical interviews, psychometric scales were applied.

Intervention type: OTHER
Intervention: Clinical interviews, psychometric scales were applied.
Study: NCT00849134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1482160 or placebo
Description: GSK1482160 is a P2X7 receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1482160 or placebo
Description: GSK1482160 is a P2X7 receptor antagonist
Study: NCT00957749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cPMP
Description: Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
Study: NCT06318819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Floss Holders
Description: Dental Floss Holders for flossing purposes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Floss Holders
Description: Dental Floss Holders for flossing purposes
Study: NCT00980018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Participants received two 150 \[a total of 300 mg at each dosing\] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules \[a total of 400 mg at each dosing\] for patients enrolled prior to Protocol Amendment 1).
Study: NCT01280682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: anti-CD20 monoclonal antibody 125mg/m\^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
Study: NCT01472939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSP-002358 (0.1 mg) + PPI
Description: 0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSP-002358 (0.5 mg) + PPI
Description: 0.5 mg tablet t.i.d. taken in addition to a PPI
Study: NCT03619889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual pressure release technique on trigger points.
Description: A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A simulated pressure release technique is applied around masticatory and neck muscles.
Study: NCT05251857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animation Education Program Applied to Laparoscopic Sleeve Gastrectomy Patients
Description: Behavioral: Animation Education Program The investigators will apply Animation Education Program.
Study: NCT03371537

Intervention type: PROCEDURE
Intervention: Liver debit measure
Description: Mesure of liver debit during hepatectomy
Study: NCT00536081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: 6 mg s.c. 24-36 h post-chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg s.c. 24-36 h post-chemotherapy
Study: NCT02999932

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SpO2 directed oxygen therapy
Description: Oxygen therapy was administered to achieve targeted SpO2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SpO2 directed oxygen therapy
Description: Oxygen therapy was administered to achieve targeted SpO2.
Study: NCT03577756

Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.

Intervention type: OTHER
Intervention: Neurodevelopmental assessments
Description: Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
Study: NCT02705625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-711
Description: MIV-711 administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIV-711
Description: MIV-711 administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured to mimic MIV-711 capsule.
Study: NCT00329550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
Study: NCT02205047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil or Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil or Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil or Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: D2 gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastrectomy
Description: D2 gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy
Description: D2 gastrectomy
Study: NCT02072798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
Study: NCT01628289

Intervention type: OTHER
Group type: OTHER
Intervention: charging a co-payment for Diabetic Retinopathy screening
Description: The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.

Intervention type: OTHER
Group type: OTHER
Intervention: free screening without charging a co-payment
Description: The intervention is to provide free screening without charging a co-payment
Study: NCT01871168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Infusion of 0.5-1% lidocaine

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham TAP block
Description: Infusion of saline
Study: NCT04106583

Intervention type: DEVICE
Intervention: WAVE, as part of the SMART COIL System
Description: WAVE, as part of the SMART COIL System
Study: NCT03820570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hernia repair
Description: inguinal hernia repair
Study: NCT04561583

Intervention type: DEVICE
Group type: OTHER
Intervention: LED light source system for endoscope
Description: This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pinpoint Endoscopic Fluorescence Imaging System
Description: This trial is designed as a prospective, multi-center, single-blind, parallel, randomized controlled clinical trial. The trial will be carried out in 5 centers, involving 220 subjects as estimated who will be divided into the test group or control group randomly on an equal basis (each group includes 110 subjects).~This trial will be carried out in 4 stages, including the screening period, random grouping, operation date and follow-up period. In the screening period, the informed consent forms are collected and inclusion and exclusion criteria are verified; after that, the accepted subjects will be randomly divided into the control group or test group; on the operation date, the operation is carried out using the device; safety follow-up visit is carried out during the follow-up period.
Study: NCT03978078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: - Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
Study: NCT02145897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stromal Vascular Fraction (SVF)
Description: Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose Derieved MSCs
Description: Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT00875615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
Study: NCT02352077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold with BMMCs or MSCs transplantation
Description: Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
Study: NCT03730662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study: NCT01472939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSP-002358 (2.0 mg) + PPI
Description: 2.0 mg tablet t.i.d. taken in addition to a PPI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + PPI
Description: Placebo t.i.d. taken in addition to a PPI
Study: NCT00664703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeline sulfate
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeline sulfate
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeline sulfate
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
Study: NCT02843958

Intervention type: DEVICE
Group type: OTHER
Intervention: HEMOPTIC
Study: NCT03403777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
Study: NCT03783481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile community
Description: Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Mobile community
Description: No Mobile community
Study: NCT03069560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS
Description: SMS contact from the caregiver with patient after discharge in intervention group
Study: NCT02701751

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise session
Description: A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
Study: NCT01115491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
Study: NCT00363896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
Study: NCT00322608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-2358
Description: Treatment on Days 1, 8 and 15 in a 28 day cycle
Study: NCT05142410

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of post-translational histone modifications via mass spectrometry
Description: During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4).

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of post-translational histone modifications via mass spectrometry
Description: During the GrossHist study (NCT04205383), only 3 post-translational histone modifications available in ELISA at the time were quantified thanks to a collaboration with the VOLITION™ company \[Bouvier and Fortier et al. 2021\]. The development of a new mass spectrometry approach based on nucleosome enrichment of plasma, developed by collaborators at VOLITION™, has made it possible to consider the description of all post-translational histone modifications (about 40 post-translational modifications involving histones H2A, H2B, H3 and H4).